- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04032574
Efficacy and Tolerability of a Phytotherapy Combination (Aqualibra) in Patients With Uncomplicated Cystitis (AquUTI)
Multicenter, Randomized, Double-blind, Placebo-controlled Parallel Group Trial to Evaluate the Efficacy and Tolerability of a Phytotherapy Combination (Aqualibra) in Patients With Uncomplicated Cystitis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This randomized, placebo-controlled, double-blind study investigated the efficacy and safety of the herbal medicinal product containing a combination of extracts of restharrow root (Ononidis radix), Java tea (Orthosiphonis folium) and goldenrod herb (Solidaginis herba) in the treatment of acute lower uUTI. The herbal medicinal product represent a multi-target therapy that includes diuretic, anti-inflammatory and antimicrobial aspects.
Patients were randomized to one of the two treatment groups and treated with the phytotherapeutic agent or matching placebo for seven days.
The primary endpoint was microbiologic response defined as reduction in bacterial urine culture counts by at least 10*2 CFU/ml.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Female outpatients aged 18-75 years
- Diagnosis of acute lower uUTI occurring for the first time or acute relapse of chronic recurrent uUTI
- Typical symptoms of cystitis (pollakisuria, dysuria and urgency)
- Bacterial count of 10*4 - 10*6 colony forming units (CFU)/mL in midstream urine
- Presence of >20 leukocytes/µL of urine measured by dipstick test
- No antibiotic treatment required according to the investigator
- Women of childbearing potential were allowed to participate only if they used a highly effective method of contraception
- Written informed consent
Exclusion Criteria:
- Known hypersensitivity to any of the active substances or excipients of the study medication
- Antibiotic treatment during the past 8 days or indication for antibiotic treatment for the current infection
- Patients with trichomoniasis, chlamydiosis or gonorrhoea
- Use of concomitant medication that may have an effect on the UTI, including other phytotherapeutics with similar effects, saluretics (including those in antihypertensives) or other drugs with a similar mode of action, urinary acidifying agents (e.g. Acimethin®), antibiotics, or phytotherapeutics with possible antibiotic effects
- Patients with suspected ovarian inflammation (e.g. adnexitis)
- Patients with suspected renal inflammation (e.g. pyelonephritis)
- Patients with complicated UTI (e.g. obstruction, stones, reflux)
- Patients with overactive bladder
- Patients with vegetative urogenital syndrome
- Patients who were currently participating or had participated in another clinical trial within 30 days before enrolment
- Patients in poor general condition
- Alcohol- or drug-addicted patients
- Pregnant or nursing women or women not using highly effective methods of contraception
- Patients with mental illness or no/limited legal capacity
- Patients held in an institution by legal or official order
- Patients who were not proficient in spoken or written German
- Patients with a urine bacterial count >10*6 CFU/mL were to be excluded from further participation in the study unless they specifically wished to continue treatment with the study medication.
- No contraindications against the study medication were known at the time of study protocol preparation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Herbal medicinal product
three times daily two film coated tablets containing: extracts of restharrow root (Ononidis radix) 80mg,Java tea (Orthosiphonis folium) 90mg, goldenrod herb (Solidaginis herba) 180mg
|
|
Placebo Comparator: Placebo
three times daily two film coated tablets
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
microbiologic response
Time Frame: 7 days
|
Percentage of patients with a reduction in bacterial urine culture counts by at least 10*2 CFU/ml
|
7 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Leukocyturia
Time Frame: 7 days
|
Percentage of patients without leukocyturia
|
7 days
|
Collaborators and Investigators
Investigators
- Study Director: Roland Fischer, PhD, Medice Arzneimittel Pütter GmbH & CoKG
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 97.019/91
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Urinary Tract Infection Lower Acute
-
Lee's Pharmaceutical LimitedCompletedAcute Lower Urinary Tract InfectionChina
-
University of IbadanRecruitingUrinary Tract Infections | Urinary Tract Infection Lower AcuteNigeria
-
China Academy of Chinese Medical SciencesGuangdong Provincial Hospital of Traditional Chinese Medicine; Chengdu University... and other collaboratorsUnknownUrinary Tract Infection Lower Acute
-
Wuerzburg University HospitalUniversity of Bristol; University of Georgia; LMU Klinikum; University of Wuerzburg and other collaboratorsRecruitingMedication Adherence | Antibiotic Resistant Infection | Urinary Tract Infection Lower Acute | Urinary Tract Infection Bacterial | Cystitis AcuteGermany
-
Baylor Research InstituteForte MedicalCompletedLower Urinary Tract Symptoms | Lower Urinary Tract InfectionUnited States
-
Altesa Biosciences, Inc.Virtus Respiratory ResearchRecruitingRCT of Vapendavir in Patients With COPD and Human Rhinovirus/Enterovirus Upper Respiratory InfectionInfections | Virus Diseases | Respiratory Tract Infections | Respiratory Tract Diseases | Lung Diseases | Pulmonary Disease, Chronic Obstructive | Enterovirus Infections | Copd | Pulmonary Disease | Respiratory Disease | Respiratory Complication | Upper Respiratory Tract Infections | Respiratory Viral Infection | ... and other conditionsUnited Kingdom
-
Iterum Therapeutics, International LimitedCompletedAntibiotic Resistant Infection | UTI - Lower Urinary Tract InfectionUnited States
-
The Christ HospitalUnknownLower Urinary Tract Symptoms | Postoperative Urinary Tract InfectionUnited States
-
University of Colorado, DenverBiofireCompletedAcute Respiratory Infection | Lower Respiratory Tract Illness | Respiratory Pathogens | Upper Respiratory Tract IllnessUnited States
-
University of GöttingenCuretis AG, Holzgerlingen, GermanyCompletedPneumonia | Acute Lower Respiratory Tract InfectionGermany
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States